Dihydrocodeine 30mg tablets

国家: 英国

语言: 英文

来源: MHRA (Medicines & Healthcare Products Regulatory Agency)

现在购买

资料单张 资料单张 (PIL)
25-12-2022
产品特点 产品特点 (SPC)
30-11--0001

有效成分:

Dihydrocodeine tartrate

可用日期:

M & A Pharmachem Ltd

ATC代码:

N02AA08

INN(国际名称):

Dihydrocodeine tartrate

剂量:

30mg

药物剂型:

Oral tablet

给药途径:

Oral

类:

Schedule 5 (CD Inv)

处方类型:

Valid as a prescribable product

產品總結:

BNF: 04070200; GTIN: 5056205100200 5056205100217

资料单张

                                5HDGDOORIWKLVOHDIOHWFDUHIXOO\EHIRUH\RXVWDUWWDNLQJ
WKLVPHGLFLQHEHFDXVHLWFRQWDLQVLPSRUWDQWLQIRUPDWLRQ
IRU\RX


.HHSWKLVOHDIOHW
                                
                                阅读完整的文件
                                
                            

产品特点

                                OBJECT 1
DIHYDROCODEINE 30MG TABLETS
Summary of Product Characteristics Updated 20-Jun-2019 | M & A
Pharmachem Ltd
•
1. Name of the medicinal product
•
2. Qualitative and quantitative composition
•
3. Pharmaceutical form
•
4. Clinical particulars
•
4.1 Therapeutic indications
•
4.2 Posology and method of administration
•
4.3 Contraindications
•
4.4 Special warnings and precautions for use
•
4.5 Interaction with other medicinal products and other forms of
interaction
•
4.6 Fertility, pregnancy and lactation
•
4.7 Effects on ability to drive and use machines
•
4.8 Undesirable effects
•
4.9 Overdose
•
5. Pharmacological properties
•
5.1 Pharmacodynamic properties
•
5.2 Pharmacokinetic properties
•
5.3 Preclinical safety data
•
6. Pharmaceutical particulars
•
6.1 List of excipients
•
6.2 Incompatibilities
•
6.3 Shelf life
•
6.4 Special precautions for storage
•
6.5 Nature and contents of container
•
6.6 Special precautions for disposal and other handling
•
7. Marketing authorisation holder
•
8. Marketing authorisation number(s)
•
9. Date of first authorisation/renewal of the authorisation
•
10. Date of revision of the text
1. Name of the medicinal product
Dihydrocodeine Tablets BP 30 mg
2. Qualitative and quantitative composition
Each tablet contains 30 mg Dihydrocodeine Tartrate
3. Pharmaceutical form
Tablet
4. Clinical particulars
4.1 Therapeutic indications
Dihydrocodeine tablets are indicated for the relief of moderate to
severe pain.
4.2 Posology and method of administration
For oral administration
The analgesic effect is not materially enhanced by increasing the dose
above that recommended below; in
severe cases the interval between doses should be reduced to obtain
the requisite analgesic cover.
Dihydrocodeine tablets are best taken with or after food.
Adults and children over 12 years: 1 tablet every four to six hours or
at the discretion of the practitioner.
Maximum dose in 24 hours 180mg (6 tablets).
Elderly
A reduced adult dose is recommended, at the 
                                
                                阅读完整的文件
                                
                            

搜索与此产品相关的警报